Free Trial
NASDAQ:IRMD

iRadimed Q3 2025 Earnings Report

iRadimed logo
$71.08 +0.66 (+0.94%)
Closing price 04:00 PM Eastern
Extended Trading
$71.13 +0.05 (+0.07%)
As of 06:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

iRadimed EPS Results

Actual EPS
N/A
Consensus EPS
$0.43
Beat/Miss
N/A
One Year Ago EPS
N/A

iRadimed Revenue Results

Actual Revenue
N/A
Expected Revenue
$20.50 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

iRadimed Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Thursday, October 30, 2025
Conference Call Time
11:00AM ET

Conference Call Resources

iRadimed Earnings Headlines

iRadimed (NASDAQ:IRMD) vs. Spectral AI (NASDAQ:MDAI) Financial Contrast
Trump Devises the Death of the IRS ☠️
Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-changing system designed to replace income taxes and send direct payouts to everyday Americans. More than $1 TRILLION is expected to be distributed... and YOU could be eligible to claim a massive check.tc pixel
Does IRADIMED (NASDAQ:IRMD) Deserve A Spot On Your Watchlist?
Iradimed Appoints Joe Kiani as New Director
See More iRadimed Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like iRadimed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on iRadimed and other key companies, straight to your email.

About iRadimed

iRadimed (NASDAQ:IRMD) designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites. These include safety filters, pressure transducers and patient temperature management systems, all optimized for operation within high-field magnetic environments. The company’s focus on reliability and regulatory compliance supports clinical use in hospitals, imaging centers and research institutions worldwide.

Founded in 1999 and headquartered in Winter Springs, Florida, iRadimed serves a global customer base through direct sales and international distributors across North America, Europe, Asia and Latin America. Its products are used in applications such as neuroimaging, cardiac imaging and oncology protocols where precise fluid delivery under MRI guidance is critical.

iRadimed completed its initial public offering in 2011 and is traded on the NASDAQ under the symbol IRMD. John B. Reininga, the company’s founder, serves as President and Chief Executive Officer, guiding product innovation and strategic growth in the specialized field of MRI-compatible medical devices.

View iRadimed Profile

More Earnings Resources from MarketBeat